Combinations of therapeutic agents for treating cancer

摘要

A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

主权项

1. A method for treating proliferative disease comprising administering pharmaceutically and synergistically effective amounts of a combination of:
(a) 7-t-butoxyiminomethylcamptothecin; and (b) one or more chemotherapeutic agents selected from paclitaxel, wherein the proliferative disease is non-small cell lung cancer, and the administration is simultaneous, concurrent, separate or sequential; docetaxel, wherein the proliferative disease is selected from the group consisting of breast cancer, prostate cancer, non-small cell lung cancer and ovarian cancer, and the administration is simultaneous, concurrent, separate or sequential; epothilone B, wherein the proliferative disease is selected from the group consisting of lung cancer, prostate cancer and ovarian cancer, and the administration is sequential; cisplatinum, wherein the proliferative disease is non-small cell lung cancer or ovarian cancer and wherein 7-t-butoxyiminomethylcamptothecin is administered followed by cis-platinum; carboplatin, wherein the proliferative disease is selected from the group consisting of ovarian cancer and non-small cell lung cancer and the administration is simultaneous, concurrent, separate or sequential; {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-ethyl)-amine, wherein the proliferative disease is selected from lung cancer, melanoma, renal cell adenocarcinoma, ovary adenocarcinoma, renal cell adenocarcinoma, pancreas epithelioid carcinoma, myeloma, colorectal adenocarcinoma, cervical carcinoma and pancreatic carcinoma, and the administration is simultaneous, concurrent, separate or sequential; everolimus, wherein the proliferative disease is selected from the group consisting of non-small cell lung cancer, ovary adenocarcinoma, pancreas epithelioid carcinoma and colorectal adenocarcinoma, and the administration is simultaneous, concurrent, separate or sequential; imatinib, wherein the proliferative disease is selected from the group consisting of non-small cell lung cancer, ovary adenocarcinoma, renal cell adenocarcinoma, pancreatic carcinoma, pancreas epithelioid carcinoma and colorectal adenocarcinoma, and the administration is simultaneous, concurrent, separate or sequential; or bortezomib, wherein the proliferative disease is selected from the group consisting of ovary adenocarcinoma, melanoma and colorectal adenocarcinoma, and the administration is simultaneous, concurrent, separate or sequential.